BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives $11.00 Average Price Target from Brokerages

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has earned an average rating of “Hold” from the four research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $11.00.

BTAI has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Friday, July 17th. Wall Street Zen cut shares of BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th.

BioXcel Therapeutics Stock Performance

BioXcel Therapeutics stock opened at $0.12 on Friday. The firm has a market capitalization of $3.68 million, a PE ratio of -0.03 and a beta of 0.19. BioXcel Therapeutics has a one year low of $0.11 and a one year high of $4.29. The stock’s 50 day moving average price is $0.87 and its 200 day moving average price is $1.14.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.05). The business had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.48 million. On average, analysts forecast that BioXcel Therapeutics will post -2.7 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BTAI. Millennium Management LLC increased its holdings in BioXcel Therapeutics by 78.5% during the 4th quarter. Millennium Management LLC now owns 1,835,192 shares of the company’s stock worth $2,936,000 after purchasing an additional 807,139 shares during the last quarter. Man Group plc purchased a new position in shares of BioXcel Therapeutics during the 4th quarter valued at approximately $91,000. State Street Corp grew its position in shares of BioXcel Therapeutics by 19.9% during the fourth quarter. State Street Corp now owns 63,218 shares of the company’s stock worth $101,000 after buying an additional 10,500 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of BioXcel Therapeutics in the fourth quarter worth $204,000. Finally, Geode Capital Management LLC increased its stake in shares of BioXcel Therapeutics by 64.6% in the fourth quarter. Geode Capital Management LLC now owns 206,168 shares of the company’s stock worth $330,000 after buying an additional 80,928 shares during the last quarter. Hedge funds and other institutional investors own 30.68% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.